Subcutaneous blinatumomab treatment for adults with CD19-positive mixed phenotype acute leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, non-randomized, open-label phase II study of subcutaneous blinatumomab in adults with CD19-positive MPAL. Participants are enrolled into one of three cohorts: newly diagnosed older or unfit patients (Cohort A), patients in remission but with measurable residual disease ≥0.1% (Cohort B), and patients with morphologic relapsed or refractory disease (Cohort C). The regimen uses repeated subcutaneous doses with scheduled clinic visits for safety monitoring, response assessments including MRD testing, and supportive care; select post–allo-HSCT patients are eligible under protocol conditions. Primary endpoints target efficacy within each cohort (clinical response or MRD clearance) alongside collection of safety and tolerability data.

Why it matters

Who can join: the full rules

* Inclusion Criteria:
* General Criteria for all three Cohorts

  * Subjects must have histologically or cytologically confirmed MPAL based on 2022 WHO criteria
  * Subjects who have undergone allo-HSCT are eligible if they are ≥ 4 weeks post stem cell infusion, have no evidence of GVHD \> Grade 2, and are at least ≥ 1 week off of immunosuppressive therapy. Per FDA recommendation, patients should be off of calcineurin inhibitors (CNIs) for at least 4 weeks before receiving blinatumomab
  * Subjects with a CNS leukemia must be clinically stable (i.e., asymptomatic with no focal neurological signs and symptoms, or signs and symptoms unchanged over 4 weeks with no \> grade 2 manifestations) with a flow cytometric clear CSF in the 2 weeks prior to day 1 of SC-blinatumomab administration.
  * Ability to understand and willingness to sign a written informed consent document
  * Agree to comply with the study requirements and agree to come to the clinic/hospital for required study visits
  * Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry
* Specific Criteria for Cohort A

  o Subjects should be ineligible for available induction therapy either if they are 75 years of age or older or if they have at least one of the following coexisting conditions precluding intensive chemotherapy: a history of CHF for which treatment is warranted or a report of EF ≤50% in the last 12 months, a history of chronic stable angina, a report of DLCO of ≤65% or FEV1 ≤65% in the last 12 months, ECOG performance status 3 or 4, Charlson comorbidity index (CCI) ≥3.
* Specific Criteria for Cohort B

  * CD19+ MPAL in CR/CRh/CRi after at least one line of treatment with MRD positivity at a level of ≥0.1% using an assay with a minimum sensitivity of 0.01%.
  * ECOG performance status ≤2
  * Subjects must have organ function as below:

    * Direct bilirubin ≤ 2.5 mg/dL
    * AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal
    * Serum creatinine ≤ 3 mg/dL
* Specific Criteria for Cohort C

  * Confirmed R/R CD19+ MPAL
  * Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed by 5 half-lives of the drug(s) prior to day 1 of SC-blinatumomab. Per FDA recommendation, patients should have recovered to no more than Grade 1 toxicities from prior chemotherapy.
  * ECOG performance status ≤2
  * Subjects must have organ function as below:

    * Direct bilirubin ≤ 2.5 mg/dL
    * AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal
    * Serum creatinine ≤ 3 mg/dL
* Exclusion Criteria:
* Criteria for all three Cohorts

  * Subjects receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy for cancer treatment not including corticosteroids or hydroxyurea
  * Active, uncontrolled infection; subjects with infection under active treatment and controlled with antimicrobials are eligible

Where it's running

• West Virginia University Cancer Institute
  Morgantown, West Virginia, United States Recruiting

Study contacts

• Principal investigator: Ashkan Emadi, MD — WVU Cancer Institute
• Study coordinator: Ashkan Emadi, MD
• Email: MPALStudyWVUCI@hsc.wvu.edu
• Phone: 304-293-5949

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blinatumomab plus low-dose donor cells after transplant for high-risk B-ALL

  This small, early-phase study tests whether giving blinatumomab with low-dose donor lymphocytes after allogeneic transplant is safe and helps long-term survival for people with high-risk B-ALL.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07677878

• LP-118 in combination with standard therapy for newly diagnosed Ph+ ALL

  This study tests whether adding LP-118 to the standard therapy for adults with Philadelphia chromosome–positive ALL is safe and useful.

  Recruiting at 2 sites Phase 1 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT07614022

• MK-1045 versus blinatumomab for relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia

  This trial will test whether MK-1045 helps people with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia more than the standard immunotherapy blinatumomab.

  Recruiting at 30 sites Phase 2/3 Merck Sharp & Dohme LLC · Toronto, Ontario and 29 other locations · NCT07570173

• Vaccine protection after blinatumomab in children with B-ALL

  This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.

  Recruiting at 2 sites Arkansas Children's Hospital Research Institute · Little Rock, Arkansas and 1 other locations · NCT07422337

• Asciminib in children and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL

  This study tests asciminib in kids and young adults with relapsed or refractory Philadelphia-positive or ABL-class Ph-like ALL to see if it is safe and helps treat the leukemia.

  Recruiting at 4 sites Phase 1/2 Novartis · Sydney, New South Wales and 3 other locations · NCT07387926

• Erwinia asparaginase and venetoclax added to blinatumomab for relapsed/refractory CD19+ B‑ALL

  This will test whether adding recombinant Erwinia asparaginase and venetoclax to blinatumomab helps adolescents and adults (12–55) with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07133997

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.